Skip to content

Investor Relations / Publications / Cardiovascular Outcomes Trials

Cardiovascular Outcomes Trials

To search publications using the available search words, please click here:

Boden WE, Bhatt DL, Toth PP, et al. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. Eur Heart J. 2020;41(24):2304–2312.

Bhatt DL, Miller M, Brinton EA, Jacobson TA, Steg G, Ketchum SB, Doyle RT Jr., Juliano RA, Jiao L, Granowitz C, Tardif J-C, Olshansky B, Chung MK, Gibson CM, Giugliano RP, Budoff MJ, Ballantyne CM, on behalf of the REDUCE-IT Investigators. REDUCE-IT USA: results from the 3,146 patients randomized in the United States. Circulation. 2019; epub ahead of print.

Amarin Corporation